Subsequent studies support MGMT promoter methylation as a predictive biomarker in glioblastoma, but the exact role in guiding clinical management is still being refined, partly due to challenges in testing methodology and establishing meaningful cutoffs for the assays [79]. The gene discussed is MGMT; the disease is glioblastoma.